Discussion
Based on extensive publicly available genetic data, we investigated the causal relationship between various factors, including 41 inflammatory cytokines, 731 immune cell traits, and 1400 metabolites, and the disease outcome of BA. To our knowledge, this is the first MR analysis to explore causal relationships with BA at multiple levels. Our study identified three inflammatory cytokines (eotaxin, G-CSF, MCP-1/MCAF), three immune cell traits (CD8dim NKT counts, CD8dim NKT/T cells ratio, CD8dim NKT/lymphocyte ratio), and one metabolite (X-12261 levels) as having a significant causal relationship with BA.
The expression of each of the three inflammatory factors was a risk factor for BA, respectively, consistent with previous studies. Udomsinprasert et al23 found that eotaxin, G-CSF, and MCP-1 levels were higher in the blood of children with BA. Increased eotaxin levels were notably linked to adverse outcomes such as jaundice, fibrosis, and portal hypertension. Moreover, the study identified MCP-1 as a potentially sensitive and specific biomarker for BA, with significantly upregulated relative mRNA expression observed in BA livers.
MCP-1 may play an important role in the development of BA with progressive liver fibrosis. Glucocorticoid treatment can regulate the expression of MCP-1 in the liver of cholestatic rats and reduce the infiltration of inflammatory cells.24 25 Ramm et al26 found that bile acid-induced upregulation of hepatocyte-derived MCP-1 expression led to the recruitment of hepatic stellate cells and was a critical early event in the development of liver fibrosis. Jafri et al27 found that chemokines expressed by rhesus rotavirus-infected cholangiocytes, such as MCP-1, might trigger host inflammatory processes leading to bile duct obstruction.
In a phase 1 study exploring Kasai-G-CSF sequential therapy for BA, G-CSF safely mobilized hematopoietic stem cells in Kasai children, potentially enhancing short-term biliary drainage and mitigating cholangitis.28 Nonetheless, the efficacy outcomes of sequential adjuvant Kasai and G-CSF therapy in phase 2 have yet to be determined. Intriguingly, another study observed high expression of G-CSF in the liver tissues of children with BA.23 While our findings suggest that G-CSF is a risk factor for BA, discrepancies between MR analysis and validation results might occur, influenced by factors such as insufficient sample size and small effect size. Hence, for G-CSF, we will further validate its relationship with BA in subsequent studies.
Our study revealed a decrease in the risk of BA with increasing CD8dim NKT counts, CD8dim NKT/T cells ratio, and CD8dim NKT/lymphocyte ratio. Notably, the association between CD8dim NKT counts and BA had not been previously reported. Previous research on the connection between BA and CD8+ T cells showed that a higher degree of CD8+ T cell infiltration in the bile duct of children with BA was correlated with better liver function.29 In addition, Kotb et al30 observed a greater mean CD4+/CD8+ ratio in children who died within eighteen months after the Kasai procedure than in other children with BA.
Our study has several strengths. First, the two-sample MR study design helps reduce bias present in observational association studies, stemming from residual confounding and reverse causality. Second, we systematically investigated the causal relationship between multiple levels of data (including inflammatory cytokines, immune cell traits, and metabolites) and BA. Third, we employed seven MR methods to assess the robustness of causal associations and effect directions, including IVW, MR-Egger, weighted median, weighted mode, simple mode, MR-PRESSO, and MR-Steiger.
However, there are limitations to consider. First, we did not further subdivide BA considering the classification of the original data. Second, the power of IVs relies heavily on the sample size of GWAS, necessitating more data to enhance accuracy. Third, while MR analysis is reliable for assessing causality, it cannot replace randomized controlled trials (RCTs). Therefore, inferred causal relationships may not align with those observed in RCTs and require further validation in future studies. Fourth, our study relied on the Euro-American cohort for GWAS data, limiting the generalizability of our findings to other ethnic groups.
In conclusion, our study used publicly available GWAS data and MR analysis to identify three inflammatory cytokines (eotaxin, G-CSF, MCP-1/MCAF) and one metabolite X-12261 as risk factors for BA with a significant causal relationship. Three immune cell characteristics (CD8dim NKT counts, CD8dim NKT/T cells ratio, CD8dim NKT/lymphocyte ratio) also had a significant causal relationship with BA, and they were protective factors for BA. These findings contributed to a new genetic understanding of BA’s etiology, diagnosis, and potential treatment strategies. In our subsequent work, we will evaluate the accuracy of three inflammatory cytokines in the early diagnosis of BA using clinical samples. Furthermore, we will use in vivo and in vitro experiments along with multi-omics techniques to further investigate the involvement of these three inflammatory cytokines and CD8dim NKT cells in the pathogenesis of BA, exploring their specific roles in disease progression.